BDX Quote, Financials, Valuation and Earnings

Baxter International has a net margin of 7.36% compared to Becton Dickinson &'s net margin of 5.19%. Becton Dickinson &'s return on equity of 6.63% beat Baxter International's return on equity of 1.33%.

Becton Dickinson & has a consensus price target of $278.80, signalling upside risk potential of 18.93%. On the other hand Baxter International has an analysts' consensus of $40.08 which suggests that it could grow by 35.47%. Given that Baxter International has higher upside potential than Becton Dickinson &, analysts believe Baxter International is more attractive than Becton Dickinson &.

Becton Dickinson & has a beta of 0.393, which suggesting that the stock is 60.666% less volatile than S&P 500. In comparison Baxter International has a beta of 0.596, suggesting its less volatile than the S&P 500 by 40.4%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.66%. Baxter International offers a yield of 3.52% to investors and pays a quarterly dividend of $0.17 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Baxter International pays out 22.06% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.4B, which are larger than Baxter International quarterly revenues of $2.7B. Becton Dickinson &'s net income of $400M is higher than Baxter International's net income of $140M. Notably, Becton Dickinson &'s price-to-earnings ratio is 39.47x while Baxter International's PE ratio is 147.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 3.38x versus 0.87x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 7.36% compared to Becton Dickinson &'s net margin of 11.12%. Becton Dickinson &'s return on equity of 6.63% beat Boston Scientific's return on equity of 8.91%.

Becton Dickinson & has a consensus price target of $278.80, signalling upside risk potential of 18.93%. On the other hand Boston Scientific has an analysts' consensus of $100.08 which suggests that it could grow by 4.31%. Given that Becton Dickinson & has higher upside potential than Boston Scientific, analysts believe Becton Dickinson & is more attractive than Boston Scientific.

Becton Dickinson & has a beta of 0.393, which suggesting that the stock is 60.666% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.800, suggesting its less volatile than the S&P 500 by 20.007%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.66%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Boston Scientific pays out 1.76% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.4B, which are larger than Boston Scientific quarterly revenues of $4.2B. Becton Dickinson &'s net income of $400M is lower than Boston Scientific's net income of $468M. Notably, Becton Dickinson &'s price-to-earnings ratio is 39.47x while Boston Scientific's PE ratio is 79.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 3.38x versus 8.94x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems has a net margin of 7.36% compared to Becton Dickinson &'s net margin of 8.37%. Becton Dickinson &'s return on equity of 6.63% beat Merit Medical Systems's return on equity of 9.56%.

Becton Dickinson & has a consensus price target of $278.80, signalling upside risk potential of 18.93%. On the other hand Merit Medical Systems has an analysts' consensus of $113.70 which suggests that it could grow by 15.86%. Given that Becton Dickinson & has higher upside potential than Merit Medical Systems, analysts believe Becton Dickinson & is more attractive than Merit Medical Systems.

Becton Dickinson & has a beta of 0.393, which suggesting that the stock is 60.666% less volatile than S&P 500. In comparison Merit Medical Systems has a beta of 0.850, suggesting its less volatile than the S&P 500 by 14.956%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.66%. Merit Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Merit Medical Systems pays out -- of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.4B, which are larger than Merit Medical Systems quarterly revenues of $339.8M. Becton Dickinson &'s net income of $400M is higher than Merit Medical Systems's net income of $28.4M. Notably, Becton Dickinson &'s price-to-earnings ratio is 39.47x while Merit Medical Systems's PE ratio is 47.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 3.38x versus 4.35x for Merit Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 7.36% compared to Becton Dickinson &'s net margin of 25.43%. Becton Dickinson &'s return on equity of 6.63% beat ResMed's return on equity of 23.76%.

Becton Dickinson & has a consensus price target of $278.80, signalling upside risk potential of 18.93%. On the other hand ResMed has an analysts' consensus of -- which suggests that it could grow by 8.54%. Given that Becton Dickinson & has higher upside potential than ResMed, analysts believe Becton Dickinson & is more attractive than ResMed.

Becton Dickinson & has a beta of 0.393, which suggesting that the stock is 60.666% less volatile than S&P 500. In comparison ResMed has a beta of 0.698, suggesting its less volatile than the S&P 500 by 30.155%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.66%. ResMed offers a yield of 0.86% to investors and pays a quarterly dividend of $0.53 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.4B, which are larger than ResMed quarterly revenues of $1.2B. Becton Dickinson &'s net income of $400M is higher than ResMed's net income of $311.4M. Notably, Becton Dickinson &'s price-to-earnings ratio is 39.47x while ResMed's PE ratio is 31.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 3.38x versus 7.25x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.